News Story

PBD Biotech to speak at Liverpool School of Tropical Medicine anniversary celebrations

The UK’s first Centre for Phage Research is being officially launched on 16th May and featured in the UK KTN UK Phage Innovation Showcase will be Actiphage®, a phage-based molecular diagnostic for tuberculosis.

Accurate and rapid drug resistance testing is essential for early diagnosis of both drug-sensitive and drug-resistant TB.

We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic tests that are urgently needed to screen LTBI and determine who will progress to active TB disease.

The role of phage-based laboratory diagnostics in the detection of tuberculosis is to be discussed in a live webinar hosted by the AACC, it has been announced ahead of World TB Day.

Tuberculosis testing and treatment needs to happen close to the point of infection. PBD Biotech has developed a lyophilized PCR reaction bead for its Actiphage® blood test for active TB. This enables ambient shipping without the need for a cold...

PBD Biotech has obtained grant of its patent application for its Actiphage® incipient tuberculosis diagnostic within the regional African Intellectual Property Organization (OAPI). This covers the mainly French-speaking countries of West Africa.

PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.

Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need, PBD Biotech is announcing that it has appointed Dr Marie Roskrow to chair its board and has expanded its scientific...

Creating a shared language for talking about tuberculosis has been identified by the Stop TB Partnership as being a constructive step towards achieving the United Nations political declaration to eliminate TB by 2030.

Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been revealed by the TAG pipeline report

The Global Plan to End TB is a costed public health plan. It aims to cut deaths by 90% in 8 years. A key recommendation of the report is to universally replace sputum microscopy with rapid molecular diagnostics.